Mesoblast Limited (ASX:MSB) Equity Report By OzEquitiesMonday June 30 5:26 PMThe following are exerpts from a featured stock report in "OzEquities": Mesoblast - Mesoblast Ltd is at the forefront of next generation technology using adult human stem cells, the treatment that will increasingly replace or augment current "mechanical" intervention through surgery - whether in renewing worn out or damaged joints, or rejuvenating injured hearts. - Where Mesoblast and Angioblast's technology exceeds its competitors in its attraction is that it has patented technology to use donor stem cells - "allogeneic" cells - that can become available immediately or "off the shelf" to patients in need with none of the time delay of up to six weeks necessary for the harvesting and culture of the patient's own "autologous" stem cells. Mesoblast's allogeneic stem cells have been accepted by all patients treated so far with no trace of immune reaction or rejection. This forms the basis of a business model akin to a pharmaceutical drug, with low costs of goods and high margins. - Mesoblast's 39.2 pct owned sister company, Angioblast in the US, has equity investment from global healthcare company, Abbott, and there are also collaborations with Johnson and Johnson companies Cordis Corporation and Biosense Webster. Other collaborations with the major pharmas seem imminent - and will transform market perception of this unique company and its technology. - Trading at below $1, the stock has descended from around $2.50 a year and a half ago, despite the huge advances made by the company since then, and the comparatively short road remaining to commercialisation. For investors with a three year view, an investment now is likely to be handsomely repaid. - A treatment that is safe, that works, that is comparatively inexpensive both to produce and to purchase due to its ability to be frozen for virtual "off the shelf" instant treatment, that can potentially deliver 90 pct plus profit margins to the company on a comparable basis to a pharmaceutical - a treatment that also eliminates the expenses involved in cultivating a patient's own stem cells - and that in many cases means repeat doses on a six monthly, yearly or 5 year basis - offers Mesoblast an immense opportunity. About MESOBLAST LIMITED: Mesoblast Limited (ASX: MSB; USOTC:MBLTY.AX) is an Australian biotechnology company committed to the development of novel treatments for orthopaedic conditions, including the rapid commercialisation of a unique adult stem cell technology aimed at the regeneration and repair of bone and cartilage. Our focus is to progress through clinical trials and international regulatory processes necessary to commercialise the technology in as short a timeframe as possible. Mesoblast has the worldwide exclusive rights for a series of patents and technologies that have been developed over more than 10 years and which relate to the identification, extraction and culture of adult Mesenchymal Precursor Cells (MPCs). The Company has also acquired a substantial interest in Angioblast Systems Inc, an American company developing the platform MPC technology for the treatment of cardiovascular diseases, including repair and regeneration of blood vessels and heart muscle. Mesoblast and Angioblast are jointly funding and progressing the core technology. Mesoblast's strategy is to maximise shareholder value through both corporate partnerships and the rapid and successful completion of clinical milestones. Contact: Julie Meldrum Corporate Communications Director Mesoblast Limited T: +61-3-9639-6036 M: +61-419-228-128 E: julie.meldrum@mesoblast.com W: www.mesoblast.com Source: MESOBLAST LIMITED Copyright (C) 2008 ABN Newswire. All rights reserved. |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright ©
2008
Yahoo!7 Pty Limited. All rights reserved.
Advertise with Us -
Privacy Policy - Terms of Service.